New 15-Strain HPV vaccine trial aims to broaden cancer protection
NCT ID NCT06756269
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new 15-valent HPV vaccine to see if it is safe and triggers a strong immune response. It involves 330 healthy Chinese volunteers aged 9 to 45. Participants will receive three doses of the vaccine or a placebo, and researchers will monitor side effects and measure antibody levels. The goal is to protect against more HPV types than current vaccines.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENITAL WART are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
RECRUITINGNanning, Guangxi, 530028, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a daily supplement help the body fight off HPV?
- At-Home HPV tests could save lives of women with HIV
- New immune therapy aims to train body to clear HPV
- Could a tiny HPV shot still protect? small study tests lower dose
- New Self-Sampling and digital colposcopy could speed up cervical cancer detection
- Tailored radiation beams aim to outsmart aggressive throat cancer